BRPI0919296A2 - biomarcadores urinários para prevenção de díalise de longa duração - Google Patents

biomarcadores urinários para prevenção de díalise de longa duração

Info

Publication number
BRPI0919296A2
BRPI0919296A2 BRPI0919296A BRPI0919296A BRPI0919296A2 BR PI0919296 A2 BRPI0919296 A2 BR PI0919296A2 BR PI0919296 A BRPI0919296 A BR PI0919296A BR PI0919296 A BRPI0919296 A BR PI0919296A BR PI0919296 A2 BRPI0919296 A2 BR PI0919296A2
Authority
BR
Brazil
Prior art keywords
prevention
long
term dialysis
urinary biomarkers
biomarkers
Prior art date
Application number
BRPI0919296A
Other languages
English (en)
Inventor
John A Kellum Jr
Kai Singbartl
Original Assignee
Univ Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pittsburgh filed Critical Univ Pittsburgh
Publication of BRPI0919296A2 publication Critical patent/BRPI0919296A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G01N2400/38—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, e.g. Konjac gum, Locust bean gum, Guar gum
    • G01N2400/40—Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
BRPI0919296A 2008-09-26 2009-09-24 biomarcadores urinários para prevenção de díalise de longa duração BRPI0919296A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10058808P 2008-09-26 2008-09-26
US12/565,483 US8501489B2 (en) 2008-09-26 2009-09-23 Urinary biomarkers to predict long-term dialysis
PCT/US2009/005296 WO2010036342A2 (en) 2008-09-26 2009-09-24 Urinary biomarkers for predicting long-term dialysis

Publications (1)

Publication Number Publication Date
BRPI0919296A2 true BRPI0919296A2 (pt) 2015-12-15

Family

ID=42057868

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0919296A BRPI0919296A2 (pt) 2008-09-26 2009-09-24 biomarcadores urinários para prevenção de díalise de longa duração

Country Status (12)

Country Link
US (4) US8501489B2 (pt)
EP (1) EP2344882B1 (pt)
JP (1) JP5479480B2 (pt)
KR (1) KR101680392B1 (pt)
CN (1) CN102216776B (pt)
AU (1) AU2009297098C1 (pt)
BR (1) BRPI0919296A2 (pt)
CA (1) CA2737779C (pt)
HK (1) HK1160927A1 (pt)
MX (1) MX2011003174A (pt)
NZ (1) NZ592473A (pt)
WO (1) WO2010036342A2 (pt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102187220B (zh) * 2008-08-28 2015-08-19 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
JP5947544B2 (ja) * 2008-08-29 2016-07-06 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後のための方法および組成物
US8501489B2 (en) 2008-09-26 2013-08-06 University of Pittsburgh—of the Commonwealth System of Higher Education Urinary biomarkers to predict long-term dialysis
NZ619918A (en) * 2008-10-21 2015-04-24 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CA2740788C (en) * 2008-10-21 2023-03-14 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2009313189B2 (en) 2008-11-10 2014-10-23 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
ES2528799T3 (es) * 2008-11-22 2015-02-12 Astute Medical, Inc. Métodos para el pronóstico de insuficiencia renal aguda
US9229010B2 (en) 2009-02-06 2016-01-05 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
DE102009010563A1 (de) 2009-02-16 2010-08-26 Matthias W. Engel Vorrichtung zum Nachweis von Analyten in Körperflüssigkeiten
EP2462440B1 (en) 2009-08-07 2017-05-17 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP2013510322A (ja) 2009-11-07 2013-03-21 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
CN104698161A (zh) 2009-12-20 2015-06-10 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
US20170074868A1 (en) * 2009-12-20 2017-03-16 Astute Medical, Inc. Methods and compositions for the evaluation of renal injury using hyaluronic acid
WO2012040592A1 (en) 2010-09-24 2012-03-29 Astute Medical, Inc. Methods and compositions for the evaluation of renal injury using hyaluronic acid
CN102791885B (zh) 2010-02-05 2015-09-09 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
US9029093B2 (en) 2010-02-26 2015-05-12 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2011269775B2 (en) 2010-06-23 2015-01-15 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP3339859A1 (en) 2010-06-23 2018-06-27 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US10557856B2 (en) * 2010-09-24 2020-02-11 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Biomarkers of renal injury
US8486717B2 (en) 2011-01-18 2013-07-16 Symbolics, Llc Lateral flow assays using two dimensional features
WO2012102963A1 (en) * 2011-01-26 2012-08-02 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Urine biomarkers for prediction of recovery after acute kidney injury : proteomics
WO2013086359A1 (en) 2011-12-08 2013-06-13 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US9874556B2 (en) 2012-07-18 2018-01-23 Symbolics, Llc Lateral flow assays using two dimensional features
US20150241415A1 (en) * 2012-08-11 2015-08-27 Astute Medical, Inc. Evaluating renal injury using hyaluronic acid
EP3361255B1 (en) 2013-01-17 2020-03-11 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US9599615B2 (en) 2013-03-13 2017-03-21 Symbolics, Llc Lateral flow assays using two dimensional test and control signal readout patterns
US10765834B2 (en) 2015-07-20 2020-09-08 Strataca Systems Limited Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion
US11040180B2 (en) 2015-07-20 2021-06-22 Strataca Systems Limited Systems, kits and methods for inducing negative pressure to increase renal function
US11541205B2 (en) 2015-07-20 2023-01-03 Roivios Limited Coated urinary catheter or ureteral stent and method
US11040172B2 (en) 2015-07-20 2021-06-22 Strataca Systems Limited Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion
US11229771B2 (en) 2015-07-20 2022-01-25 Roivios Limited Percutaneous ureteral catheter
US10926062B2 (en) 2015-07-20 2021-02-23 Strataca Systems Limited Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion
US10512713B2 (en) 2015-07-20 2019-12-24 Strataca Systems Limited Method of removing excess fluid from a patient with hemodilution
RU2720403C2 (ru) 2015-07-20 2020-04-29 Стратака Системз Лимитед, Мт Мочеточниковый катетер и мочепузырный катетер и способы создания отрицательного давления для увеличения почечной перфузии
US10918827B2 (en) 2015-07-20 2021-02-16 Strataca Systems Limited Catheter device and method for inducing negative pressure in a patient's bladder
US10493232B2 (en) 2015-07-20 2019-12-03 Strataca Systems Limited Ureteral catheters, bladder catheters, systems, kits and methods for inducing negative pressure to increase renal function
CA3026502A1 (en) 2016-06-06 2017-12-14 Astute Medical, Inc. Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2
US11059740B2 (en) 2017-06-02 2021-07-13 Guardian Glass, LLC Glass article containing a coating with an interpenetrating polymer network
WO2019032746A1 (en) 2017-08-08 2019-02-14 Fresenius Medical Care Holdings, Inc. SYSTEMS AND METHODS FOR TREATING AND ESTIMATING THE PROGRESSION OF CHRONIC RENAL DISEASE
KR102012899B1 (ko) * 2017-09-27 2019-08-21 전남대학교산학협력단 급성신장손상으로 인한 신장대체요법 중단시기 결정방법 및 중단시기결정용 진단키트
KR102319190B1 (ko) * 2018-12-19 2021-10-29 서울대학교병원 신장 질환 진단용 바이오 마커
KR102077987B1 (ko) * 2018-12-19 2020-02-17 주식회사 헬릭스미스 신장 질환 진단용 바이오 마커
CN112881562A (zh) * 2021-02-07 2021-06-01 苏州大学附属第一医院 葡糖醛酸作为慢性肾脏病早期诊断标志物的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6350571B1 (en) * 1996-02-01 2002-02-26 Vinata B. Lokeshwar Methods for detection and evaluation of bladder cancer
EP0922222A1 (en) * 1996-02-01 1999-06-16 The University Of Miami Methods for detection and evaluation of bladder cancer
JP3846973B2 (ja) * 1997-06-06 2006-11-15 生化学工業株式会社 慢性炎症の判定方法及びキット
US7138230B2 (en) * 2002-12-06 2006-11-21 Renovar, Inc. Systems and methods for characterizing kidney diseases
WO2005017686A2 (en) 2003-08-05 2005-02-24 Sepaton, Inc. Emulated storage system
CN1869702A (zh) * 2005-05-24 2006-11-29 穆海东 肝炎与肝硬化的集成检测反应板和蛋白芯片试剂盒
EP1970709B1 (en) 2007-03-06 2013-07-10 Roche Diagnostics GmbH The use of BNP-type peptides for predicting the need for dialysis
US8501489B2 (en) 2008-09-26 2013-08-06 University of Pittsburgh—of the Commonwealth System of Higher Education Urinary biomarkers to predict long-term dialysis

Also Published As

Publication number Publication date
EP2344882B1 (en) 2017-05-10
CA2737779C (en) 2018-05-22
CN102216776B (zh) 2015-01-28
EP2344882A2 (en) 2011-07-20
JP5479480B2 (ja) 2014-04-23
KR20110097760A (ko) 2011-08-31
WO2010036342A2 (en) 2010-04-01
CN102216776A (zh) 2011-10-12
JP2012503772A (ja) 2012-02-09
AU2009297098A1 (en) 2010-04-01
KR101680392B1 (ko) 2016-11-28
US9057722B2 (en) 2015-06-16
US20150330975A1 (en) 2015-11-19
MX2011003174A (es) 2011-09-15
WO2010036342A9 (en) 2010-07-08
AU2009297098C1 (en) 2015-07-30
NZ592473A (en) 2012-11-30
AU2009297098B2 (en) 2015-01-22
HK1160927A1 (en) 2012-08-17
US8815602B2 (en) 2014-08-26
CA2737779A1 (en) 2010-04-01
US20100081148A1 (en) 2010-04-01
EP2344882A4 (en) 2013-01-23
US9389222B2 (en) 2016-07-12
US8501489B2 (en) 2013-08-06
US20130299427A1 (en) 2013-11-14
US20140329256A1 (en) 2014-11-06

Similar Documents

Publication Publication Date Title
BRPI0919296A2 (pt) biomarcadores urinários para prevenção de díalise de longa duração
BRPI0906706A2 (pt) Conjuntos de válvulas
BRPI0924008A2 (pt) cuecas funcionais para homens
BRPI0915984A2 (pt) método para inibição da corrosão
BRPI0722200A2 (pt) Método para calibração de setores
BRPI0911175A8 (pt) conjunto de válvula
BRPI0813981A2 (pt) agonistas sintéticos da tlr9.
BRPI1013082A2 (pt) marcadores de risco para enfermidade cardiovascular
BRPI1012680A2 (pt) cateter urinário
BRPI0920069A2 (pt) biomarcadores
DK2370716T3 (da) Ventilanordning
BRPI0907637A2 (pt) Biomarcadores p53
BRPI0906812A2 (pt) Mitigação de reluzência do lcd.
FR2947559B1 (fr) Fluides de laminage
BRPI0807980A2 (pt) Polímero de não-polialfaolefinas dispersos para redução de arraste
DE112009000197T8 (de) Schiermittelzusammensetzung
DK2103820T3 (da) Fikseringsenhed
BRPI0917375A2 (pt) composicoes e metodos para fornecimento de um beneficio
NO20091124L (no) Sammenstilling for rorlegging
ES1067292Y (es) Filtro para grifos
DK2517018T3 (da) Biomarkører
ES1065835Y (es) Caperuza para cetreria
BRPI0919732A2 (pt) composicoes e metodos para inibicao da expressao de transtirretina
ES1068469Y (es) Valvula para fluidos
ES1068830Y (es) Mampara para ducha

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: PAGAR RESTAURACAO.

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE RPI 2384 DE 13/09/2016

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements